Drug General Information
Drug ID	D0E7FM
Former ID	DNCL002734
Drug Name	GTx-758
Indication	Advanced prostate cancer [ICD9: 185; ICD10:C61]		Phase 2	[523416]
Company	GTx
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Estrogen receptor	Target Info	Modulator	[532859]
KEGG Pathway	Estrogen signaling pathway
	Prolactin signaling pathway
	Thyroid hormone signaling pathway
	Endocrine and other factor-regulated calcium reabsorption
	Proteoglycans in cancer
NetPath Pathway	FSH Signaling Pathway
	EGFR1 Signaling Pathway
	RANKL Signaling Pathway
Pathway Interaction Database	Regulation of nuclear SMAD2/3 signaling
	Signaling events mediated by HDAC Class II
	Plasma membrane estrogen receptor signaling
	LKB1 signaling events
	Regulation of Telomerase
	ATF-2 transcription factor network
	AP-1 transcription factor network
	FOXM1 transcription factor network
	Validated nuclear estrogen receptor alpha network
	Signaling mediated by p38-alpha and p38-beta
	FOXA1 transcription factor network
Reactome	Nuclear signaling by ERBB4
	Nuclear Receptor transcription pathway
WikiPathways	Estrogen signaling pathway
	Nuclear Receptors Meta-Pathway
	Estrogen Receptor Pathway
	Signaling by ERBB4
	JAK/STAT
	Integrated Pancreatic Cancer Pathway
	Leptin signaling pathway
	miR-targeted genes in muscle cell - TarBase
	Integrated Breast Cancer Pathway
	Nuclear Receptors
References
Ref 523416	ClinicalTrials.gov (NCT01326312) Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer. U.S. National Institutes of Health.
Ref 532859	Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015 Feb;67(2):334-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.